BioCentury | Jun 23, 2020
Product Development

June 22 Quick Takes: Invitae acquiring ArcherDX; plus lymphoma approval for Karyopharm, Merck, Nabriva, Myovant, Assembly-AbbVie, Genentech and more

...with moderate to severe atopic dermatitis. NIH stops hydroxychloroquine trial On Saturday, NIH stopped its ORCHID...
BioCentury | May 12, 2020
Politics, Policy & Law

FDA’s hydroxychloroquine test

...its EUA decision. FDA may be waiting for results from the 510-patient randomized, controlled NIH-funded ORCHID...
...April. Study completion is scheduled for July, but some results could be announced sooner. If ORCHID...
BioCentury | Apr 21, 2020
Product Development

After pledging to donate millions of hydroxychloroquine doses, Novartis readies trial to assess drug’s benefit for COVID-19

...combination with the antibiotic azithromycin. NIH and Massachusetts General Hospital are running the Phase III ORCHID...
BioCentury | Apr 10, 2020
Product Development

COVID-19 roundup: New immune targets to address pandemic; plus updates from CanSino, Arcturus, Fujifilm and more

...than 500 adults hospitalized with COVID-19, or in an emergency department with anticipated hospitalization. The ORCHID...
BioCentury | Oct 8, 2015
Product R&D

Medicines Co.'s double play

...Not applicable Hospital-acquired bacterial infections Fedora Pharmaceuticals Inc. FPI-1465 Not applicable Not applicable Bacterial infections Orchid...
BioCentury | Apr 21, 2014
Company News

Actavis, Apotex, Dr. Reddy's, Mylan, Orchid Chemicals & Pharmaceuticals, Roche musculoskeletal news

...be effective in previous studies. Roche filed suit against Actavis, Apotex, Dr. Reddy's, Mylan and Orchid...
...Toronto, Ontario Dr. Reddy's Laboratories Ltd. (NYSE:RDY), Hyderabad, India Mylan Inc. (NASDAQ:MYL), Canonsburg, Pa. Orchid...
BioCentury | Feb 27, 2014
Targets & Mechanisms

The XII factor

...Archemix Corp.; Arca biopharma Inc. (NASDAQ:ABIO) ARC2172 (aptamer) Phase I Block coagulation Diakron Pharmaceutical Inc.; Orchid...
BioCentury | May 13, 2013
Emerging Company Profile

Allecra: Secret weapon vs. bacteria

...to multidrug-resistant Gram-negative bacteria. The company will advance at least two preclinical compounds acquired from Orchid...
...April co-led by Edmond de Rothschild Investment Partners and Forbion Capital Partners, with participation by Orchid...
...is one of the compounds acquired from Orchid. "The patents that we have acquired from Orchid...
BioCentury | Mar 26, 2012
Clinical News

Boniva ibandronate regulatory update

...treat and prevent postmenopausal osteoporosis. Apotex Inc. (Toronto, Ontario); Mylan Inc. (NASDAQ:MYL, Canonsburg, Pa.); and Orchid...
BioCentury | Feb 20, 2012
Company News

Nanologica infectious, drug delivery news

...Materials development company Nanologica joined the ORCHID alliance to improve the formulation and solubility of water-insoluble...
...porous carrier materials to control the release of active compounds through porous particles. The four-year ORCHID...
...EU is directly contributing €5.4 million ($7.2 million) in funding to the project. Members of ORCHID...
Items per page:
1 - 10 of 235
BioCentury | Jun 23, 2020
Product Development

June 22 Quick Takes: Invitae acquiring ArcherDX; plus lymphoma approval for Karyopharm, Merck, Nabriva, Myovant, Assembly-AbbVie, Genentech and more

...with moderate to severe atopic dermatitis. NIH stops hydroxychloroquine trial On Saturday, NIH stopped its ORCHID...
BioCentury | May 12, 2020
Politics, Policy & Law

FDA’s hydroxychloroquine test

...its EUA decision. FDA may be waiting for results from the 510-patient randomized, controlled NIH-funded ORCHID...
...April. Study completion is scheduled for July, but some results could be announced sooner. If ORCHID...
BioCentury | Apr 21, 2020
Product Development

After pledging to donate millions of hydroxychloroquine doses, Novartis readies trial to assess drug’s benefit for COVID-19

...combination with the antibiotic azithromycin. NIH and Massachusetts General Hospital are running the Phase III ORCHID...
BioCentury | Apr 10, 2020
Product Development

COVID-19 roundup: New immune targets to address pandemic; plus updates from CanSino, Arcturus, Fujifilm and more

...than 500 adults hospitalized with COVID-19, or in an emergency department with anticipated hospitalization. The ORCHID...
BioCentury | Oct 8, 2015
Product R&D

Medicines Co.'s double play

...Not applicable Hospital-acquired bacterial infections Fedora Pharmaceuticals Inc. FPI-1465 Not applicable Not applicable Bacterial infections Orchid...
BioCentury | Apr 21, 2014
Company News

Actavis, Apotex, Dr. Reddy's, Mylan, Orchid Chemicals & Pharmaceuticals, Roche musculoskeletal news

...be effective in previous studies. Roche filed suit against Actavis, Apotex, Dr. Reddy's, Mylan and Orchid...
...Toronto, Ontario Dr. Reddy's Laboratories Ltd. (NYSE:RDY), Hyderabad, India Mylan Inc. (NASDAQ:MYL), Canonsburg, Pa. Orchid...
BioCentury | Feb 27, 2014
Targets & Mechanisms

The XII factor

...Archemix Corp.; Arca biopharma Inc. (NASDAQ:ABIO) ARC2172 (aptamer) Phase I Block coagulation Diakron Pharmaceutical Inc.; Orchid...
BioCentury | May 13, 2013
Emerging Company Profile

Allecra: Secret weapon vs. bacteria

...to multidrug-resistant Gram-negative bacteria. The company will advance at least two preclinical compounds acquired from Orchid...
...April co-led by Edmond de Rothschild Investment Partners and Forbion Capital Partners, with participation by Orchid...
...is one of the compounds acquired from Orchid. "The patents that we have acquired from Orchid...
BioCentury | Mar 26, 2012
Clinical News

Boniva ibandronate regulatory update

...treat and prevent postmenopausal osteoporosis. Apotex Inc. (Toronto, Ontario); Mylan Inc. (NASDAQ:MYL, Canonsburg, Pa.); and Orchid...
BioCentury | Feb 20, 2012
Company News

Nanologica infectious, drug delivery news

...Materials development company Nanologica joined the ORCHID alliance to improve the formulation and solubility of water-insoluble...
...porous carrier materials to control the release of active compounds through porous particles. The four-year ORCHID...
...EU is directly contributing €5.4 million ($7.2 million) in funding to the project. Members of ORCHID...
Items per page:
1 - 10 of 235